Silence Therapeutics plc (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Silence Therapeutics plc (NASDAQ:SLN) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $40.67.

SLN has been the topic of a number of recent research reports. The Goldman Sachs Group dropped their price objective on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research note on Tuesday, March 4th. Chardan Capital reiterated a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a research note on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 7th. Morgan Stanley dropped their target price on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Finally, BMO Capital Markets decreased their price target on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th.

Silence Therapeutics Stock Down 6.8 %

Shares of SLN opened at $3.44 on Monday. The business’s fifty day moving average is $4.64 and its 200 day moving average is $9.79. Silence Therapeutics has a 12-month low of $3.19 and a 12-month high of $24.38. The stock has a market cap of $102.96 million, a P/E ratio of -2.19 and a beta of 1.08.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new position in Silence Therapeutics in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC lifted its position in shares of Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after buying an additional 5,233 shares during the last quarter. Barclays PLC grew its stake in shares of Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after acquiring an additional 2,793 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Silence Therapeutics in the 4th quarter worth about $69,000. Finally, Virtus ETF Advisers LLC raised its stake in Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after acquiring an additional 6,098 shares during the period. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.